Literature DB >> 17182598

Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma.

Tomoya Tsuchiyama1, Yasunari Nakamoto, Yoshio Sakai, Yohei Marukawa, Masaaki Kitahara, Naofumi Mukaida, Shuichi Kaneko.   

Abstract

Tumor recurrence rates remain high after curative treatments for hepatocellular carcinoma (HCC). Immunomodulatory agents, including chemokines, are believed to enhance the antitumor effects of tumor cell apoptosis induced by suicide gene therapy. We therefore evaluated the immunomodulatory effects of a bicistronic recombinant adenovirus vector (rAd) expressing both HSV thymidine kinase and MCP-1 on HCC cells. Using an athymic nude mouse model (BALB/c-nu/nu), primary s.c. tumors (HuH7; human HCC cells) were completely eradicated by rAd followed by treatment with ganciclovir. The same animals were subsequently rechallenged with HCC cells, tumor development was monitored, and the recruitment or activation of NK cells was analyzed immunohistochemically or by measuring IFN-gamma mRNA expression. Tumor growth was markedly suppressed as compared with that in mice treated with a rAd expressing the HSV thymidine kinase gene alone (p < 0.001). Suppression of tumor growth was associated with the elevation of serum IL-12 and IL-18. During suppression, NK cells were recruited exclusively, and Th1 cytokine gene expression was enhanced in tumor tissues. The antitumor activity, however, was abolished either when the NK cells were inactivated with anti-asialo GM1 Ab or when anti-IL-12 and anti-IL-18 Abs were administered. These results indicate that suicide gene therapy, together with delivery of MCP-1, eradicates HCC cells and exerts prolonged NK cell-mediated antitumor effects in a model of HCC, suggesting a plausible strategy to prevent tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17182598     DOI: 10.4049/jimmunol.178.1.574

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Chemokines and their receptors play important roles in the development of hepatocellular carcinoma.

Authors:  Chun-Min Liang; Long Chen; Heng Hu; Hui-Ying Ma; Ling-Ling Gao; Jie Qin; Cui-Ping Zhong
Journal:  World J Hepatol       Date:  2015-06-08

2.  Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes.

Authors:  Geoffrey J Markowitz; Pengyuan Yang; Jing Fu; Gregory A Michelotti; Rui Chen; Jianhua Sui; Bin Yang; Wen-Hao Qin; Zheng Zhang; Fu-Sheng Wang; Anna Mae Diehl; Qi-Jing Li; Hongyang Wang; Xiao-Fan Wang
Journal:  Cancer Res       Date:  2016-02-18       Impact factor: 12.701

Review 3.  Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.

Authors:  Yu-Peng Hong; Zi-Duo Li; Pankaj Prasoon; Qi Zhang
Journal:  World J Hepatol       Date:  2015-05-08

4.  FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells.

Authors:  Young Min Chung; Wen Bin Tsai; Pragya P Khan; Jessica Ma; Jonathan S Berek; James W Larrick; Mickey C-T Hu
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

5.  Dichotomous effects of cellular expression of STAT3 on tumor growth of HNSCC.

Authors:  Thomas E Bickett; Michael W Knitz; Miles Piper; Ayman J Oweida; Jacob Gadwa; Laurel B Darragh; Diemmy Nguyen; Shilpa Bhatia; Shiv Bhuvane; Andy V Phan; Benjamin Van Court; Sophia Corbo; Tiffany Pham; Alexander L Dent; Laurel Lenz; Sana D Karam
Journal:  Mol Ther       Date:  2021-11-15       Impact factor: 11.454

6.  Naïve rat umbilical cord matrix stem cells significantly attenuate mammary tumor growth through modulation of endogenous immune responses.

Authors:  Atsushi Kawabata; Naomi Ohta; Garret Seiler; Marla M Pyle; Susumu Ishiguro; Yong Qing Zhang; Kevin G Becker; Deryl Troyer; Masaaki Tamura
Journal:  Cytotherapy       Date:  2013-03-07       Impact factor: 5.414

Review 7.  The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?

Authors:  Marco Puzzoni; Nicola Silvestris; Francesco Leone; Riccardo Giampieri; Luca Faloppi; Laura Demurtas; Emanuela Dell'Aquila; Donatella Marino; Oronzo Brunetti; Silvio Ken Garattini; Elena Ongaro; Giorgio Astara; Laura Orgiano; Giuseppe Aprile; Daniele Santini; Mario Scartozzi
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

Review 8.  Immune cell recruitment and cell-based system for cancer therapy.

Authors:  Jian-Qing Gao; Naoki Okada; Tadanori Mayumi; Shinsaku Nakagawa
Journal:  Pharm Res       Date:  2007-09-22       Impact factor: 4.200

Review 9.  Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment.

Authors:  Naofumi Mukaida; So-ichiro Sasaki; Tomohisa Baba
Journal:  Mediators Inflamm       Date:  2014-05-22       Impact factor: 4.711

Review 10.  Regulation of Natural Killer Cell Function by STAT3.

Authors:  Nicholas A Cacalano
Journal:  Front Immunol       Date:  2016-04-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.